Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Objectives To evaluate the efficacy, safety, and tolerability of lubiprostone in patients
with nonalcoholic fatty liver disease (NAFLD).
This study will include 100 patients with nonalcoholic fatty liver disease (NAFLD) recruited
from the specialized NAFLD outpatient's clinic in National Hepatology and Tropical Medicine
Research Institute (NHTMRI).
Study design: Randomized controlled trial.